title: [A clinicopathologic and prognosis study of Epstein-Barr virus positive diffuse large B-cell lymphoma in west-southern China].
abstract: OBJECTIVE
  To investigate the clinicopathologic features, immunophenotype, and the prognosis related factors of Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL) in west-southern China.
  
  
  METHODS
  There were 42 cases of EBV+ DLBCL in a total 586 DLBCL, the clinical and pathologic profiles of these patients were evaluated. Immunohistochemical study and in situ hybridization (ISH) of EBER1/2 were performed on formalin fixed tissues by tissue chips. The prognosis related factors were analyzed.
  
  
  RESULTS
  The median age of these 42 EBV+ DLBCL patients was 62.5 years. The male-to-female ratio was 2.23 : 1. The site of occurrence included lymph node (69.05%) and spleen, stomach, tonsil, nasal cavity and nasopharynx. The mostly common initial clinical presentations were non-specific symptoms, such as lymphadenopathy, splenomegaly, hepatomegaly, fever, and fatigue. Morphologically, the majority (90.48%, 38/42) were pleomorphic subtypes and only 4 cases (9.52%) were simplex subtypes. Immunophenotype showed non-GCB type of DLBCL was predominance (83.33%, 35/42) by Hans classification. The expression of CD30, CD5, BCL-2, P53 and NF-kappaB/ P65 were 52.38% (22/42), 54.76% (23/42), 54.76% (23/42), 87.5% (35/40) and 0% (0/40) respectively. Follow-up data was available in 23 (54.76%) patients, 14 (60.87%) patients died of the tumor. 5-years overall survival was 16.5%. The median survival time was 40 months. The expression of BCL-2, increased LDH level and starry-sky morphologic character were associated with a poor prognosis.
  
  
  CONCLUSIONS
  EBV positive DLBCL is not uncommon. Most lesions locate in lymph nodes. Pleomorphic histologic subtype is predominant. The tumor has worse prognosis with increased LDH level, starry-sky morphologic character and BCL-2 expression.
authors.forename: Yun-Xia
authors.initials: YX
authors.lastname: Ye
authors.forename: Wen-Yan
authors.initials: WY
authors.lastname: Zhang
authors.forename: Gan-Di
authors.initials: GD
authors.lastname: Li
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Liu
authors.forename: Yan-Mei
authors.initials: YM
authors.lastname: Liu
authors.forename: Li
authors.initials: L
authors.lastname: Lin
authors.forename: Dian-Ying
authors.initials: DY
authors.lastname: Liao
authors.forename: Jia
authors.initials: J
authors.lastname: Guo
authors.forename: Chun-Yan
authors.initials: CY
authors.lastname: Xie
authors.forename: Wei-Jie
authors.initials: WJ
authors.lastname: Jiang
authors.forename: Li
authors.initials: L
authors.lastname: Liu
authors.forename: Shang-Fu
authors.initials: SF
authors.lastname: Zhang
mesh_terms: D002681:China; D020031:Epstein-Barr Virus Infections; D005260:Female; D005500:Follow-Up Studies; D004854:Herpesvirus 4, Human; D006801:Humans; D016130:Immunophenotyping; D017403:In Situ Hybridization; D016403:Lymphoma, Large B-Cell, Diffuse / Q000821:virology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012367:RNA, Viral / Q000378:metabolism
chemical_list: C099537:Epstein-Barr virus encoded RNA 1; D012367:RNA, Viral